Clinical Edge Journal Scan

Multiple sclerosis: Greater prevalence of disease activity in women and disability accrual in men


 

Key clinical point: Women vs men with multiple sclerosis (MS) showed greater inflammatory disease activity up to menopausal age, whereas men vs women with MS showed greater disability accrual.

Major finding: Women vs men had a 16% higher relapse rate and a higher estimated marginal mean of annualized relapse rate (0.32 vs 0.28; P < .001); however, the difference disappeared after the age of 50 years. The deterioration in the Expanded Disability Status Scale (EDSS) points was higher in men vs women (0.065 vs 0.049 EDSS points per year; P = .0017), with men at a higher risk of reaching EDSS 4 ( P < .001).

Study details: Findings are from an analysis of 9647 patients (3028 men and 6619 women) with MS from the Danish MS registry (DMSR) who received disease-modifying therapy and were followed-up for at least 1 year and two control visits.

Disclosures: The DMSR was funded by the Danish MS Society. M Magyari declared receiving consulting and speakers’ fees and serving on scientific advisory boards for various sources.

Source: Magyari M et al. Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022 (Apr 7). Doi: 10.1136/jnnp-2022-328994

Recommended Reading

Progression independent of relapse activity is a major cause of CDA in early relapsing MS
ICYMI Multiple Sclerosis
Maternal and infant outcomes in pregnant patients with MS treated with natalizumab
ICYMI Multiple Sclerosis
Patients with multiple sclerosis at an increased risk for cardiovascular diseases
ICYMI Multiple Sclerosis
Pregnancy and the risk of developing multiple sclerosis: Is there a link?
ICYMI Multiple Sclerosis
A hormone therapy shows favorable treatment satisfaction in menopausal women with MS
ICYMI Multiple Sclerosis
Clinical Edge Journal Scan Commentary: Multiple Sclerosis May 2022
ICYMI Multiple Sclerosis
Switching to extended-interval natalizumab dosing effective in RRMS
ICYMI Multiple Sclerosis
Progressive MS: sNfL shows promise as an effective biomarker for long-term disability progression
ICYMI Multiple Sclerosis
Anti-SARS-CoV-2 mAbs safe and effective for acute COVID-19 in immunocompromised patients with MS
ICYMI Multiple Sclerosis
RRMS: Long-term fingolimod shows positive benefit-risk profile in real-life settings
ICYMI Multiple Sclerosis